Explore Sanofi's latest 6-K report detailing FDA's priority review for Dupixent and a key share purchase agreement with CD&R, highlighting strategic growth and compliance.
Discover Sanofi's latest 6-K report, filed on February 13, 2025, detailing progress on an E. coli vaccine study. Stay informed on regulatory compliance and R&D efforts.
Explore Sanofi's January 2025 Form 6-K report detailing positive Sarclisa trial results and its first approval in China, enhancing its oncology portfolio and market presence.
Explore Sanofi's latest 6-K report detailing board appointments and a Phase 3 vaccine program. Stay updated on key corporate developments and regulatory compliance.
Discover Sanofi's latest Form 6-K, detailing FDA designations and promising study results for Tolebrutinib and Duvakitug, crucial for investors and stakeholders.